CM
CMPX.US Compass Therapeutics Inc.
- Market cap
- USD 139M
- P/E
- -
- P/B
- 1.04x
- ROE
- -66.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CMPX.US undervalued?
Graham numberThe Graham number of Compass Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Compass Therapeutics Inc. fundamental analysis
No fundamental analysis for Compass Therapeutics Inc. yet.
Compass Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that i…
Full company profileCompass Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Compass Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850K | 0.00 | 0.00 |
| Gross Profit | -1.92M | -2.12M | -2.40M | -1.62M | -1.90M | -1.89M | 850K | -1.47M | - |
| Operating Income | -38.3M | -34.1M | -27.8M | -81.9M | -41.7M | -50.4M | -56.6M | -72.8M | -101M |
| EBITDA | -35.7M | -31.9M | -25.4M | -80.2M | -35.0M | -40.6M | -47.6M | -65.0M | -92.7M |
| Net Income | -38.3M | -34.7M | -29.5M | -82.2M | -39.2M | -42.5M | -49.4M | -66.5M | -94.2M |
| EPS | -7.66 | -0.67 | -0.52 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.50 |
| Balance Sheet | |||||||||
| Total Assets | 64.6M | 30.4M | 51.9M | 154M | 200M | 157M | 140M | 220M | 174M |
| Total Liabilities | 149M | 149M | 12.0M | 13.7M | 18.0M | 8.34M | 15.2M | 22.8M | 31.9M |
| Shareholders' Equity | -84.8M | -119M | 39.9M | 140M | 182M | 149M | 125M | 197M | 143M |
| Cash & Short-term Investments | 57.5M | 25.3M | 47.1M | 145M | 187M | 152M | 127M | 209M | 163M |
| Total Debt | 14.8M | 14.9M | 9.33M | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M | 9.23M |
| Cash Flow | |||||||||
| Operating Cash Flow | -33.7M | -31.7M | -26.8M | -19.7M | -34.1M | -40.6M | -44.9M | -49.1M | -62.7M |
| Capital Expenditure | 2.02M | 466K | 106K | 1.57M | 212K | 30.0K | 44.0K | 25.0K | 485K |
| Free Cash Flow | -35.7M | -32.2M | -26.9M | -21.2M | -34.3M | -40.6M | -44.9M | -49.2M | -63.2M |
| Ratios | |||||||||
| ROE | - | - | -73.9% | -58.7% | -21.6% | -28.6% | -39.4% | -33.8% | -66.1% |
| ROA | -59.2% | -114.4% | -56.8% | -53.4% | -19.6% | -27.1% | -35.2% | -30.3% | -54.0% |
| Net Profit Margin | - | - | - | - | - | - | -5,808.8% | - | - |
| Debt to Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x | 0.05x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Compass Therapeutics Inc. dividends
Compass Therapeutics Inc. has not paid dividends in the last 8 fiscal years.
Who owns Compass Therapeutics Inc.
- Insiders 12.70%
- Institutions 86.44%
- Public & others 0.86%
- Shares outstanding 180M
- Free float 132M
Top funds holding CMPX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 5.16M | 2.87% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.19M | 2.33% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.38M | 1.88% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.68M | 0.93% | +0.27% | Oct 2026 |
| iShares Russell 2000 Value ETF | 1.21M | 0.67% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.06M | 0.59% | -25.96% | Aug 2026 |
| Vanguard Russell 2000 ETF | 759K | 0.42% | +0.56% | Sep 2026 |
| Fidelity Extended Market Index | 712K | 0.40% | -13.09% | Sep 2026 |
| Royce Micro-Cap Trust | 585K | 0.33% | -30.26% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 496K | 0.28% | 0.00% | Sep 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 417K | 0.23% | 0.00% | Jul 2026 |
| Vanguard Market Neutral I | 400K | 0.22% | 0.00% | Jun 2026 |
| iShares Micro-Cap ETF | 394K | 0.22% | 0.00% | Oct 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 329K | 0.18% | 0.00% | Jan 2026 |
| Schwab Small Cap Index | 322K | 0.18% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 291K | 0.16% | +0.11% | Sep 2026 |
| Fidelity Total Market Index | 278K | 0.15% | -0.05% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 278K | 0.15% | -6.51% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 246K | 0.14% | +0.03% | Oct 2026 |
| Fidelity Series Total Market Index | 240K | 0.13% | 0.00% | Sep 2026 |
Top institutions holding CMPX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 18.0M | 9.99% | +7.15% | Jun 2026 |
| Orbimed Advisors LLC | 15.2M | 8.45% | 0.00% | Jun 2026 |
| Suvretta Capital Management, LLC | 14.1M | 7.83% | -1.44% | Jun 2026 |
| BlackRock Inc | 11.3M | 6.26% | +18.68% | Jun 2026 |
| State Street Corp | 9.95M | 5.53% | +48.67% | Jun 2026 |
| Enavate Sciences GP, LLC | 7.79M | 4.32% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 7.76M | 4.31% | -18.74% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.12M | 3.40% | +1.35% | Jun 2026 |
| Palo Alto Investors, LLC | 5.83M | 3.24% | +285.06% | Jun 2026 |
| Millennium Management LLC | 4.71M | 2.62% | +456.98% | Jun 2026 |
| Geode Capital Management, LLC | 3.82M | 2.12% | +6.99% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.77M | 2.09% | +248.31% | Jun 2026 |
| Qube Research & Technologies | 3.69M | 2.05% | +44.59% | Jun 2026 |
| Blue Owl Capital Holdings LP | 3.62M | 2.01% | +23.20% | Jun 2026 |
| Citadel Advisors Llc | 3.57M | 1.98% | +394.96% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.53M | 1.96% | +76.96% | Jun 2026 |
| Rock Springs Capital Management LP | 3.52M | 1.96% | +6.64% | Jun 2026 |
| AQR Capital Management LLC | 3.51M | 1.95% | +1,650.82% | Jun 2026 |
| Birchview Capital, LP | 1.68M | 0.93% | +14.27% | Jun 2026 |
| Kingdon Capital Management LLC | 1.40M | 0.78% | 0.00% | Jun 2026 |
Compass Therapeutics Inc. company profile
- Company name
- Compass Therapeutics Inc.
- Ticker
- CMPX.US
- Exchange
- USA Stocks
- Listed since
- Apr 5, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- 80 Guest Street, Boston, MA, United States, 02135
- Phone
- 617 500 8099
- Website
- compasstherapeutics.com
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics Inc. management
10- Dr. Thomas J. Schuetz M.D., Ph.D.CEO & Vice Chairman · born 1961
- Mr. Barry Shin J.D., M.B.A.Chief Financial Officer · born 1972
- Mr. Jonathan E. Anderman J.D.Senior VP, General Counsel & Corporate Secretary · born 1983
- Mr. Neil L. Lerner CPASenior VP & Chief Accounting Officer · born 1967
- Mr. Bing Gong Ph.D.Chief Scientific Officer · born 1976
- Anna GiffordSenior Manager of Communications & Chief of Staff
- Ms. Karin Herrera B.A.Senior VP & Head of Clinical Operations
- Dr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & Controls
- Dr. Cynthia A. Sirard M.D., Ph.D.Chief Medical Officer · born 1970
- Mr. Arjun Prasad M.B.A., M.P.H.Chief Commercial Officer · born 1978